CN114128721A - Extracellular polymer inhibitor and application thereof - Google Patents
Extracellular polymer inhibitor and application thereof Download PDFInfo
- Publication number
- CN114128721A CN114128721A CN202111395154.1A CN202111395154A CN114128721A CN 114128721 A CN114128721 A CN 114128721A CN 202111395154 A CN202111395154 A CN 202111395154A CN 114128721 A CN114128721 A CN 114128721A
- Authority
- CN
- China
- Prior art keywords
- food
- borne
- concentration
- inhibitor
- sterile water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 22
- 229920000642 polymer Polymers 0.000 title claims abstract description 21
- 241000894006 Bacteria Species 0.000 claims abstract description 17
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims abstract description 15
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims abstract description 15
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims abstract description 11
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 claims abstract description 11
- 229950006790 adenosine phosphate Drugs 0.000 claims abstract description 10
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 claims description 38
- 239000004155 Chlorine dioxide Substances 0.000 claims description 19
- 235000019398 chlorine dioxide Nutrition 0.000 claims description 19
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 241000589540 Pseudomonas fluorescens Species 0.000 claims description 3
- 241000863430 Shewanella Species 0.000 claims description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- 244000052616 bacterial pathogen Species 0.000 claims description 2
- 241000206609 Porphyra Species 0.000 claims 1
- 239000012528 membrane Substances 0.000 abstract description 11
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 239000008223 sterile water Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 25
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- 239000012452 mother liquor Substances 0.000 description 8
- 239000010413 mother solution Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- UPJKSWLLCONYMW-UHFFFAOYSA-N 5'-Adenosine monophosphate Natural products COc1cc(O)c(C(=O)C)c(OC2OC(COC3OC(C)C(O)C(O)C3O)C(O)C(O)C2O)c1 UPJKSWLLCONYMW-UHFFFAOYSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229960005305 adenosine Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 239000000463 material Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N57/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
- A01N57/10—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds
- A01N57/16—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds containing heterocyclic radicals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3544—Organic compounds containing hetero rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3553—Organic compounds containing phosphorus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pest Control & Pesticides (AREA)
- Polymers & Plastics (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses an ecto-polymer inhibitor and application thereof, wherein the ecto-polymer inhibitor comprises the following components: cyclic adenosine monophosphate, 5 '-cytidylic acid and 5' -adenylic acid. The extracellular polymer inhibitor can inhibit the production of extracellular polymer by food-borne bacteria and further inhibit the formation of biological membrane by the synergistic cooperation of cyclic adenosine monophosphate, 5 '-cytidylic acid and 5' -adenylic acid.
Description
Technical Field
The invention relates to the technical field of membrane pollution removal, and particularly relates to an extracellular polymeric inhibitor and application thereof.
Background
Bacterial biofilms are widely present on various food and food processing surfaces, can cause food-borne disease outbreaks, have obvious relevance to food spoilage, and seriously restrict the healthy development of the food industry. The biofilm is an ecological community with a three-dimensional space structure, which is formed by ExtraceLLuLar Polymers (EPS) such as polysaccharide, DNA, protein and the like secreted by bacteria in order to adapt to living environment in the growth process of the bacteria. Under the protection of biofilms, bacteria exhibit up to 1000 times higher resistance to drugs than planktonic bacteria, significantly increasing food safety risks. Therefore, there is an urgent need to find a bioactive substance that has an effective effect on bacterial biofilms.
Disclosure of Invention
In order to solve the problems, the invention provides an extracellular polymeric inhibitor and application thereof, and the extracellular polymeric inhibitor can safely and efficiently eliminate the formation of food-borne bacterial biofilms.
In order to achieve the above object, embodiments of the present invention in one aspect propose an ectopolymer inhibitor comprising: cyclic adenosine monophosphate, 5 '-cytidylic acid and 5' -adenylic acid.
According to the embodiment of the invention, the ecto-polymer inhibitor can inhibit the production of ecto-polymers by food-borne bacteria and further inhibit the formation of a biological membrane by acting on key proteins for forming the biological membrane through the synergistic cooperation of cyclic adenosine monophosphate, 5 '-cytidylic acid and 5' -adenylic acid.
Optionally, the concentration of cyclic adenosine monophosphate is 0.625 mg/mL-2.5 mg/mL, the concentration of 5 '-cytidylic acid is 0.5 mg/mL-2 mg/mL, and the concentration of 5' -adenosine monophosphate is 0.5 mg/mL-2 mg/mL.
In another aspect, the embodiments of the present invention provide the use of the above-described ecto-polymer inhibitor for removing food-borne bacterial biofilms.
According to the application of the extracellular polymer inhibitor in removing food-borne bacteria biofilms, the extracellular polymer can be used for inhibiting the food-borne bacteria from generating the extracellular polymer so as to inhibit the formation of the biofilms.
Optionally, the food-borne bacteria comprise food-borne pathogenic bacteria or food-borne spoilage bacteria.
Optionally, the food-borne bacteria include escherichia coli, staphylococcus aureus, pseudomonas fluorescens, shewanella porsea.
Optionally, comprising: and adding the extracellular polymer and the chlorine dioxide solution into the food-borne bacterial biofilm.
Additional aspects and advantages of the invention will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the invention.
Drawings
FIG. 1 is a graph showing the effect of extracellular polymers on the removal of biological membranes according to an embodiment of the present invention;
FIG. 2 shows the bactericidal effect of extracellular polymers on food-borne bacteria according to an embodiment of the present invention.
Detailed Description
The technical solution of the present invention is illustrated by specific examples below. It is to be understood that one or more method steps mentioned in the present invention do not exclude the presence of other method steps before or after the combination step or that other method steps may be inserted between the explicitly mentioned steps; it should also be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Moreover, unless otherwise indicated, the numbering of the various method steps is merely a convenient tool for identifying the various method steps, and is not intended to limit the order in which the method steps are arranged or the scope of the invention in which the invention may be practiced, and changes or modifications in the relative relationship may be made without substantially changing the technical content.
In order to better understand the above technical solutions, exemplary embodiments of the present invention are described in more detail below. While exemplary embodiments of the invention have been shown, it should be understood that the invention may be embodied in various forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
The test materials adopted by the invention are all common commercial products and can be purchased in the market.
The room temperature of the invention is 25 ℃.
The invention will now be described with reference to specific examples, which are intended to be illustrative only and not to be limiting in any way.
Example 1
(1) Sterile water is used for preparing cyclic adenosine mother liquor, and the concentration is 10 mg/mL.
(2) Sterile water is used for preparing a 5' -cytidine acid mother solution, and the concentration is 10 mg/mL.
(3) Sterile water is used for preparing 5' -adenylic acid mother liquor, and the concentration is 10 mg/mL.
(4) Preparing the mother solution of chlorine dioxide with sterile water, wherein the concentration is 20 mg/mL.
(5) The overnight cultured E.coli was inoculated at 1:100 into a petri dish containing LB medium, shaken for 48h, and subjected to biofilm culture.
(6) Pouring out the culture solution, washing twice with sterile water, and adding an extracellular polymeric substance inhibitor and a chlorine dioxide solution to ensure that the final concentration of cyclic adenosine monophosphate in the system is 2.0mg/mL, 5 '-cytidylic acid is 1.0mg/mL, 5' -adenosine monophosphate is 0.5mg/mL, and the chlorine dioxide solution is 0.05 mg/mL; and lightly shaking at normal temperature to react for 0.5h to complete the removal of the biological membrane.
Example 2
(1) Sterile water is used for preparing cyclic adenosine mother liquor, and the concentration is 10 mg/mL.
(2) Sterile water is used for preparing a 5' -cytidine acid mother solution, and the concentration is 10 mg/mL.
(3) Sterile water is used for preparing 5' -adenylic acid mother liquor, and the concentration is 10 mg/mL.
(4) Preparing the mother solution of chlorine dioxide with sterile water, wherein the concentration is 20 mg/mL.
(5) The staphylococcus aureus cultured overnight is inoculated into a culture dish containing LB culture medium in a ratio of 1:100, and is shaken for 48 hours to carry out biofilm culture.
(6) Pouring out the culture solution, washing twice with sterile water, and adding an extracellular polymeric substance inhibitor and a chlorine dioxide solution to ensure that the final concentration of cyclic adenosine monophosphate in the system is 2.5mg/mL, 5 '-cytidylic acid is 1.5mg/mL, 5' -adenosine monophosphate is 1mg/mL, and the chlorine dioxide solution is 0.05 mg/mL; and lightly shaking at normal temperature to react for 0.5h to complete the removal of the biological membrane.
Example 3
(1) Sterile water is used for preparing cyclic adenosine mother liquor, and the concentration is 10 mg/mL.
(2) Sterile water is used for preparing a 5' -cytidine acid mother solution, and the concentration is 10 mg/mL.
(3) Sterile water is used for preparing 5' -adenylic acid mother liquor, and the concentration is 10 mg/mL.
(4) Preparing the mother solution of chlorine dioxide with sterile water, wherein the concentration is 20 mg/mL.
(5) The overnight cultured pseudomonas fluorescens is inoculated into a culture dish containing LB culture medium in a ratio of 1:100, and is shaken for 48 hours to carry out biofilm culture.
(6) Pouring out the culture solution, cleaning twice with sterile water, and adding an extracellular polymeric substance inhibitor and a chlorine dioxide solution to ensure that the final concentration of cyclic adenosine monophosphate in the system is 1.5mg/mL, 5 '-cytidylic acid is 1.0mg/mL, 5' -adenosine monophosphate is 1.5mg/mL, and the chlorine dioxide solution is 0.025 mg/mL; and lightly shaking at normal temperature to react for 0.5h to complete the removal of the biological membrane.
Example 4
(1) Sterile water is used for preparing cyclic adenosine mother liquor, and the concentration is 10 mg/mL.
(2) Sterile water is used for preparing a 5' -cytidine acid mother solution, and the concentration is 10 mg/mL.
(3) Sterile water is used for preparing 5' -adenylic acid mother liquor, and the concentration is 10 mg/mL.
(4) Preparing the mother solution of chlorine dioxide with sterile water, wherein the concentration is 20 mg/mL.
(5) The overnight cultured Shewanella borreliana was inoculated into a culture dish containing LB medium at a ratio of 1:100, and shaken for 48 hours to perform biofilm culture.
(6) Pouring out the culture solution, washing twice with sterile water, and adding an extracellular polymeric substance inhibitor and a chlorine dioxide solution to ensure that the final concentration of cyclic adenosine monophosphate in the system is 1.25mg/mL, 5 '-cytidylic acid is 1.0mg/mL, 5' -adenosine monophosphate is 1.25mg/mL, and the chlorine dioxide solution is 0.025 mg/mL; and lightly shaking at normal temperature to react for 0.5h to complete the removal of the biological membrane.
Comparative example 1
(1) The overnight cultured E.coli was inoculated at 1:100 into a petri dish containing LB medium, shaken for 48h, and subjected to biofilm culture.
(2) Pouring out the culture solution, washing twice with sterile water, and then adding 0.05mg/mL chlorine dioxide solution; the reaction was carried out at room temperature with gentle shaking for 0.5 h.
Comparative example 2
(1) The overnight cultured E.coli was inoculated at 1:100 into a petri dish containing LB medium, shaken for 48h, and subjected to biofilm culture.
(2) Pouring out the culture solution, washing twice with sterile water, and then adding 0.05mg/mL chlorine dioxide solution; the reaction was carried out at room temperature with gentle shaking for 0.5 h.
Comparative example 3
(1) The overnight cultured E.coli was inoculated at 1:100 into a petri dish containing LB medium, shaken for 48h, and subjected to biofilm culture.
(2) Pouring out the culture solution, washing twice with sterile water, and then adding 0.025mg/mL chlorine dioxide solution; the reaction was carried out at room temperature with gentle shaking for 0.5 h.
Comparative example 4
(1) The overnight cultured E.coli was inoculated at 1:100 into a petri dish containing LB medium, shaken for 48h, and subjected to biofilm culture.
(2) Pouring out the culture solution, washing twice with sterile water, and then adding 0.025mg/mL chlorine dioxide solution; the reaction was carried out at room temperature with gentle shaking for 0.5 h.
Test examples
And (3) carrying out a biofilm removal effect and sterilization effect test on the above examples 1-4 and comparative examples 1-4:
and (3) testing the biological membrane: removing the biofilm, removing the supernatant, gently washing with sterile water twice, oven-drying the culture dish at 80 deg.C, adding 0.1% crystal violet solution, and dyeing for 10 min. The staining solution was aspirated and washed twice with sterile water, and the petri dish was dried in an oven at 80 ℃. Dissolving in 95% ethanol, and measuring absorbance at 595 nm.
And (3) sterilization test: the biofilm was decanted to remove the supernatant, gently washed twice with sterile water, the bacteria adhered to the bottom of the dish were collected with a cell scraper, and the number of viable bacterial colonies in the biofilm was calculated by a gradient dilution coating method.
Wherein, the control group is chlorine dioxide solution with corresponding concentration only.
As shown in FIGS. 1 and 2, it can be seen from FIG. 1 that the biofilms of examples 1 to 4 were significantly eliminated by the action of the ecto-polymer inhibitor; as can be seen from FIG. 2, the number of bacteria in the biofilms of examples 1-4 was significantly reduced by the action of the ecto-polymer inhibitor.
In conclusion, the extracellular polymeric substance inhibitor prepared according to the embodiment of the invention has good biological membrane removing effect and sterilization effect, and has wide market prospect.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above should not be understood to necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples described in this specification can be combined and combined by those skilled in the art.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.
Claims (6)
1. An extracellular polymeric inhibitor, comprising: cyclic adenosine monophosphate, 5 '-cytidylic acid and 5' -adenylic acid.
2. The ecto-polymer inhibitor according to claim 1, wherein the concentration of cyclic adenosine monophosphate is 0.625mg/mL to 2.5mg/mL, the concentration of 5 '-cytidylic acid is 0.5mg/mL to 2mg/mL, and the concentration of 5' -adenylic acid is 0.5mg/mL to 2 mg/mL.
3. Use of the ecto-polymer inhibitor of claim 1 or 2 for the removal of food-borne bacterial biofilms.
4. The use of claim 3, wherein the food-borne bacteria comprise food-borne pathogenic bacteria or food-borne spoilage bacteria.
5. Use according to claim 3, wherein the food-borne bacteria comprise Escherichia coli, Staphylococcus aureus, Pseudomonas fluorescens, Shewanella Porphyra.
6. The use of claim 3, comprising: and adding the extracellular polymer and the chlorine dioxide solution into the food-borne bacterial biofilm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111395154.1A CN114128721A (en) | 2021-11-23 | 2021-11-23 | Extracellular polymer inhibitor and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111395154.1A CN114128721A (en) | 2021-11-23 | 2021-11-23 | Extracellular polymer inhibitor and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114128721A true CN114128721A (en) | 2022-03-04 |
Family
ID=80390936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111395154.1A Pending CN114128721A (en) | 2021-11-23 | 2021-11-23 | Extracellular polymer inhibitor and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114128721A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030162164A1 (en) * | 2001-04-20 | 2003-08-28 | Biolog, Inc. | Comparative phenotype analysis of cells, including testing of biologically active compounds |
| CN111269870A (en) * | 2020-03-06 | 2020-06-12 | 南京工业大学 | Recombinant escherichia coli with high cytidylic acid yield and application thereof |
-
2021
- 2021-11-23 CN CN202111395154.1A patent/CN114128721A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030162164A1 (en) * | 2001-04-20 | 2003-08-28 | Biolog, Inc. | Comparative phenotype analysis of cells, including testing of biologically active compounds |
| CN111269870A (en) * | 2020-03-06 | 2020-06-12 | 南京工业大学 | Recombinant escherichia coli with high cytidylic acid yield and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 颜日祥 等: "环化腺苷酸对细菌生长的影响", 《微生物学报》 * |
| 黄树杰 等: "《环境水处理药剂》", 31 August 2019 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yuan et al. | Mixed-species biofilms in the food industry: current knowledge and novel control strategies | |
| Liu et al. | Inhibition of biofilm formation and exopolysaccharide synthesis of Enterococcus faecalis by phenyllactic acid | |
| Marques et al. | Formation of biofilms by Staphylococcus aureus on stainless steel and glass surfaces and its resistance to some selected chemical sanitizers | |
| Foster et al. | Chitosan films are NOT antimicrobial | |
| Islama et al. | Antibacterial activity of crab-chitosan against Staphylococcus aureus and Escherichia coli | |
| Hakeem et al. | Active packaging of immobilized zinc oxide nanoparticles controls Campylobacter jejuni in raw chicken meat | |
| Ayyaru et al. | Biofouling reduction in a MBR by the application of a lytic phage on a modified nanocomposite membrane | |
| Shao et al. | The probiotic, Leuconostoc mesenteroides, inhibits Listeria monocytogenes biofilm formation | |
| Islam et al. | In vitro antibacterial activity of shrimp chitosan against Salmonella paratyphi and Staphylococcus aureus | |
| Chai et al. | Application of bacteriophage-borne enzyme combined with chlorine dioxide on controlling bacterial biofilm | |
| Hassan et al. | Microscopic observation of multispecies biofilm of various structures on whey concentration membranes | |
| Jara et al. | Role of Lactobacillus biofilms in Listeria monocytogenes adhesion to glass surfaces | |
| CN105567647A (en) | Methicillin-resistant staphylococcus epidermidis staphylococcus aureus bacteriophage and antimicrobial application thereof | |
| Iseppi et al. | Anti-listerial activity of coatings entrapping living bacteria | |
| Huang et al. | Benzalkonium bromide is effective in removing Bacillus cereus biofilm on stainless steel when combined with cleaning-in-place | |
| Sang et al. | Synthesis and preservative application of quaternized carboxymethyl chitosan containing guanidine groups | |
| Agustín et al. | Multispecies biofilms between Listeria monocytogenes and Listeria innocua with resident microbiota isolated from apple juice processing equipment | |
| Tarifa et al. | Role of hydrophobicity in adhesion of wild yeast isolated from the ultrafiltration membranes of an apple juice processing plant | |
| CN114128721A (en) | Extracellular polymer inhibitor and application thereof | |
| CN104498443A (en) | Acinetobacter baumannii phage and application thereof | |
| Lee et al. | Inhibitory effects of combinations of chemicals on Escherichia coli, Bacillus cereus, and Staphylococcus aureus biofilms during the clean-in-place process at an experimental dairy plant | |
| CN105925491A (en) | Culture medium of filamentous fungi, preparation method of culture medium and culture method of filamentous fungi by culture medium of filamentous fungi | |
| CN107177045B (en) | Collagen-lysozyme antibacterial film and preparation method thereof | |
| Allan et al. | A rapid, high-throughput method for culturing, characterizing and biocide efficacy testing of both planktonic cells and biofilms | |
| Bhosale et al. | Biofilm in the dairy industry: Detection and common process for control biofilms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220304 |
|
| RJ01 | Rejection of invention patent application after publication |